Paratek Pharmaceuticals, Inc.
PRTK · NASDAQ
6/30/2023 | 3/31/2023 | 12/31/2022 | 9/30/2022 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 30.3% | -59.8% | 160.8% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 88.5% | 78.6% | 85.8% | 84.3% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -24.1% | -53.3% | -3.4% | -58.2% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -38.2% | -69% | -9.9% | -90.7% |
| EPS Diluted | -0.25 | -0.35 | -0.13 | -0.46 |
| % Growth | 28.6% | -169.2% | 71.7% | – |
| Operating Cash Flow | -$0 | $0 | -$0 | -$0 |
| Capital Expenditures | $0 | -$0 | -$0 | $0 |
| Free Cash Flow | -$0 | $0 | -$0 | -$0 |